RegenXBio (RGNX)

RegenXBio (RGNX) Stock Price & Analysis


RGNX Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$18.69 - $35.73
Previous Close$20.13
Average Volume (3M)403.49K
Market Cap
Enterprise Value$605.08M
Total Cash (Recent Filing)$364.64M
Total Debt (Recent Filing)$94.80M
Price to Earnings (P/E)-3.1
May 09, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.50
Shares Outstanding43,293,631
10 Day Avg. Volume390,434
30 Day Avg. Volume403,491
Standard Deviation0.16
Financial Highlights & Ratios
Price to Book (P/B)1.70
Price to Sales (P/S)11.80
Price to Cash Flow (P/CF)5.70
P/FCF Ratio-5.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.37
Enterprise Value/Gross Profit10.40
Enterprise Value/Ebitda-2.48
Price Target Upside109.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9



Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was RegenXBio’s price range in the past 12 months?
RegenXBio lowest stock price was $18.69 and its highest was $35.73 in the past 12 months.
    What is RegenXBio’s market cap?
    Currently, no data Available
    When is RegenXBio’s upcoming earnings report date?
    RegenXBio’s upcoming earnings report date is May 09, 2023 which is in 49 days.
      How were RegenXBio’s earnings last quarter?
      RegenXBio released its earnings results on Feb 28, 2023. The company reported -$1.38 earnings per share for the quarter, missing the consensus estimate of -$1.283 by -$0.097.
        Is RegenXBio overvalued?
        According to Wall Street analysts RegenXBio’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does RegenXBio pay dividends?
          RegenXBio does not currently pay dividends.
          What is RegenXBio’s EPS estimate?
          RegenXBio’s EPS estimate is -$1.42.
            How many shares outstanding does RegenXBio have?
            RegenXBio has 43,463,654 shares outstanding.
              What happened to RegenXBio’s price movement after its last earnings report?
              RegenXBio reported an EPS of -$1.38 in its last earnings report, missing expectations of -$1.283. Following the earnings report the stock price went up 8.494%.
                Which hedge fund is a major shareholder of RegenXBio?
                Among the largest hedge funds holding RegenXBio’s share is Woodline Partners LP. It holds RegenXBio’s shares valued at 12M.


                  RegenXBio Stock Smart Score

                  The RegenXBio stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description


                  REGENXBIO, Inc. is a biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company was founded by Kennth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.


                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Morphic Holding
                  Lyell Immunopharma
                  Replimune Group
                  Kura Oncology

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis